-
Potential "first-in-class" allosteric activator received priority review qualification
Time of Update: 2021-09-05
Today, Agios Pharmaceuticals announced that the US FDA has accepted the new drug application (NDA) submitted by the company for mitapivat for the treatment of adult patients with pyruvate kinase (PK) deficiency .
-
Can the mRNA vaccine become the line of defense against the new crown variant?
Time of Update: 2021-09-05
In early May of this year, two real-world research data showed that Pfizer/BioNTech's BNT162b2 is more than 95% effective against serious diseases or deaths caused by Alpha and Beta variants .
-
Scientists reveal a new mechanism that regulates the fate of plant stem cells
Time of Update: 2021-09-05
Therefore, the researchers defined this stress-related signal that exists under normal growth conditions and is enriched in the stem cell microenvironment as an endogenous stress signal .
-
Pfizer's tick-borne encephalitis vaccine approved in the U.S. for active immunization of people ≥ 1 year old
Time of Update: 2021-09-05
S. Food and Drug Administration (FDA) has approved the tick-borne encephalitis (TBE) vaccine TICOVAC for active immunization of individuals ≥ 1 year old to prevent TBE .
Original source: US FDA Approves TICOVAC™, Pfizer's Tick-Borne Encephalitis (TBE) Vaccine
-
AstraZeneca launches first phase II study for first-line treatment of pancreatic ductal adenocarcinoma
Time of Update: 2021-09-05
Article source: Medical Rubik's Cube InfoAuthor: Shi BeiRecently, AstraZeneca registered the first-in-class anti-LIF monoclonal antibody AZD0171 (MSC-1) combined with anti-PD-L1 monoclonal antibody duvalizumab and chemotherapy (gemcitabine and albumin-bound paclitaxel) on the American Clinical Network Phase II clinical trial for the treatment of pancreatic ductal adenocarcinoma (PDAC) .
-
mRNA technology has another success!
Time of Update: 2021-09-05
CompilationTom LeeThis week, Moderna launched a human clinical trial of an AIDS mRNA vaccine .
Moderna to Launch Clinical Trials for mRNA-Based HIV Vaccine2.
Moderna to Trial HIV and Flu Vaccines With mRNA Technology
-
60% of patients' tumors have shrunk significantly, cancer vaccine/Keytruda combination therapy achieves positive results again
Time of Update: 2021-09-05
On August 12, 2021, Ultimovacs announced that its cancer vaccine UV1 combined with anti-PD-1 therapy Keytruda (pembrolizumab) has achieved positive top-line results in the second patient cohort (n=10) in a phase 1 clinical trial .
-
New drug carrier reduces the side effects of chemotherapy
Time of Update: 2021-09-05
Simultaneous delivery of two drugs, light controlled release drugs, tumor targetingNew drug carrier reduces the side effects of chemotherapyThe team used gold nanoparticles to hybridize the organometallic framework in situ to obtain a nanocarrier capable of simultaneously delivering chemotherapeutic drugs and immunosensitizing drugs .
-
"Cell": The most detailed molecular map of deadly lung cancer so far points out multiple treatment paths
Time of Update: 2021-09-05
It has been used as a therapeutic target in clinical trials of other types of tumors and can be used as a potential target for the treatment of lung squamous cell carcinoma .
-
Moderna 2021 Q2 financial report: 93% protection effectiveness increases 42.3 times the neutralization ability of Delta
Time of Update: 2021-09-05
Image source: Moderna 2021 Q2 financial reportIn addition, for the currently concerned strain variants, in its phase 2 clinical study, Moderna's three candidate mRNA boosters can induce wild-type D614G COVID-19 strains, Gamma (P.
-
CANCER RES: Abnormal regulation of NEIL3 is associated with poor prognosis of liver cancer
Time of Update: 2021-09-05
The research team collected the tumor and non-tumor tissues of 202 patients with primary liver cancer who underwent hepatectomy from 2010 to 2015, randomly selected 80 pairs of tumors and matched non-tumor specimens, and used immunohistochemical staining to detect NEIL3 expression levels .
-
Experts reveal the reason for mental decline after contracting new crown
Time of Update: 2021-09-05
Associate Professor Yulia Kochetova and her colleague Maria Klimakova of the Teaching and Research Section of Age Psychology, Department of Educational Psychology, Moscow City Psychology Normal University, believe that in most cases, cognitive impairment caused by the new crown virus infection is related to The work of the first structure of the brain-functional blocks is impaired .
-
Highly vigilant!
Time of Update: 2021-09-05
Can the vaccine reduce the viral load in patients with breakthrough infections and limit the spread of delta?Recently, a new study led by the University of Wisconsin in the United States explained this question.
-
O+Y approved indications and core clinical trials are sorted out
Time of Update: 2021-09-05
On the one hand, anti- CTLA-4 antibody can effectively inhibit the inhibitory signal transmitted by B7 binding; on the other hand, anti-PD-1/PD-L1 antibody can inhibit the PD-L1 binding between T cells and tumor cells) Source: Reference [2]Although the combination of nivolumab and ipilimumab, by targeting two different checkpoints (PD-1 and CTLA-4), the potential synergistic mechanism is demonstrated in a complementary manner, which has achieved a lot of hope Clinical results .
-
"Nature": Scientists accidentally discovered that a new treatment strategy for fatal "metabolic diseases" is provided
Time of Update: 2021-09-05
Because type C Niemann-Pick disease is mostly caused by mutations in the NPC1 gene, and the protein encoded by this gene is an indispensable "porter" of cholesterol in human cells .
-
"Nature" depth: Does the new crown vaccine need a third shot?
Time of Update: 2021-09-05
Not long ago, a study involving more than 30,000 people in Israel showed that over time and the decline in antibody levels, the proportion of new crown infections will increase significantly .
-
The significance is comparable to the human genome map!
Time of Update: 2021-09-05
The protein 3D structure database released today contains about 350,000 protein structures predicted by the AlphaFold artificial intelligence system, covering humans and 20 commonly used model organisms in biological research (E.
com/blog/article/putting-the-power-of-alphafold-into-the-worlds-hands[2] DeepMind and EMBL release the most complete database of predicted 3D structures of human proteins.
-
PNAS new discovery: Scientists have found a telomere regulator that can prolong life and promote cancer
Time of Update: 2021-09-05
These data indicate that the VNTR2-1 gene is the key to cell proliferation, and its deletion leads to shortening of telomeres, which affects the proliferation ability of cancer cells .
-
The mutant strain "Yota" that first appeared in New York has a higher mortality rate
Time of Update: 2021-09-05
Compared with the new coronavirus mutant strain "Yota" first discovered in New York, USA in November 2020, it has greater infectivity and immune escape tendency, and can increase the mortality rate of elderly infected persons by 62%-82% .
-
More than half of the patients' skin symptoms improved by more than 75%. Eli Lilly's eczema antibody therapy reached the phase 3 clinical endpoint
Time of Update: 2021-09-05
The test results showed that compared with placebo, lebrikizumab improved the skin symptoms of more than half of patients with moderate to severe atopic dermatitis (AD) by at least 75% (EASI 75) .
Reference materials:[1] Lilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials.
